Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatoses × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 66 Carcinoma, Hepatocellular 23 Prostatic Neoplasms 20 Neoplasm Metastasis 17 Neoplasms 15 Kidney Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Neuroendocrine Tumors 8 Carcinoma, Medullary 8 Melanoma 7 Carcinoma, Transitional Cell 7 Brain Neoplasms 7 Urinary Bladder Neoplasms 6 Sarcoma 6 Osteosarcoma 6 Colorectal Neoplasms 6 Breast Neoplasms 6 Thyroid Neoplasms 5 Sarcoma, Ewing 5 Recurrence 5 Pancreatic Neoplasms 5 Clear-cell metastatic renal cell carcinoma 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Multiple Myeloma 4 Lung Neoplasms 4 Urethral Neoplasms 3 Small Cell Lung Carcinoma 3 Liver Neoplasms 3

Interventions

mirdametinib 3 Surveys and Questionnaires 2 Imatinib Mesylate 2 tipifarnib 1 talimogene laherparepvec 1 pirfenidone 1 nilotinib 1 emvododstat 1 diphenylcyclopropenone 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sirolimus 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Magnetic Resonance Spectroscopy 1 Lidocaine 1 Lasers, Solid-State 1 Lasers 1 Glycopyrrolate 1 Dexmedetomidine 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡